Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care
- PMID: 20191081
- PMCID: PMC2828104
- DOI: 10.2147/vhrm.s9122
Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care
Abstract
Purpose: Although elevated blood pressure (BP) predicts future cardiovascular events, recommended BP targets often is not reached in the general community. In a clinical real-life setting we evaluated BP impact and tolerability of the angiotensin-II receptor blocker telmisartan in patients with essential hypertension.
Patients and methods: Patients in this observational study not at target BP started or switched to telmisartan monotherapy (40 or 80 mg) or a fixed-dose combination of telmisartan and hydrochlorothiazide (HCT) 80 mg/12.5 mg. Office and 24-hour ambulatory BP (AMBP) were measured before and after 8 weeks of treatment and physicians reported perceived drug efficacy and tolerability as "Very good", "Good", "Moderate" or "Bad".
Results: 100 patients (34% female, 60 years, BMI 29.4 kg/m(2), mean office BP 159/92 mmHg) of whom 38% were treatment naïve and 30%, 17%, 9% and 6% respectively were on 1, 2, 3 or 4 BP-lowering drugs, completed 8 weeks of treatment. The proportion of patients with office BP < 140/90 mmHg increased from 3% to 54% for systolic (P < 0.001), 38% to 75% for diastolic (P < 0.001), and 2% to 45% for systolic and diastolic BP (P < 0.001). A significant effect on BP levels was seen in patients being either treatment naïve or on 1 to 3 BP-lowering drugs at study entry, whereas no BP improvement occurred in those who switched from 4 drugs. Overall, mean 24-hour AMBP was reduced from 141/85 to 131/79 mmHg (P < 0.001). Drug efficacy and tolerability were perceived as "Very good" or "Good" by 44%/34% and 66%/27%, respectively. No drug discontinuations or serious adverse events were observed.
Conclusions: In this observational study, telmisartan 40 to 80 mg, or the fixed-dose combination telmisartan 80 mg/HCT 12.5 mg, significantly increased the number of patients reaching target BP < 140/90 mmHg if treatment naïve or previously receiving 1 to 3 BP-lowering drugs. The BP reduction achieved was sustained for 24-hour and treatment tolerability was high.
Keywords: 24-hour ambulatory blood pressure; efficacy; observational study; telmisartan; tolerability.
Figures

Similar articles
-
Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial.Blood Press Monit. 2005 Jun;10(3):157-63. doi: 10.1097/00126097-200506000-00008. Blood Press Monit. 2005. PMID: 15923818 Clinical Trial.
-
Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures.Adv Ther. 2012 Apr;29(4):327-38. doi: 10.1007/s12325-012-0013-0. Epub 2012 Apr 3. Adv Ther. 2012. PMID: 22477543
-
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.J Clin Hypertens (Greenwich). 2005 Oct;7(10):587-95; quiz 596-7. doi: 10.1111/j.1524-6175.2005.04666.x. J Clin Hypertens (Greenwich). 2005. PMID: 16227761 Free PMC article. Clinical Trial.
-
Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension.Drugs. 2008;68(13):1877-99. doi: 10.2165/00003495-200868130-00010. Drugs. 2008. PMID: 18729541 Review.
-
Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension.Expert Opin Pharmacother. 2004 Nov;5(11):2303-10. doi: 10.1517/14656566.5.11.2303. Expert Opin Pharmacother. 2004. PMID: 15500377 Review.
Cited by
-
Clinical data analysis of telmisartan for hypertension management in Indian population.Bioinformation. 2021 Jun 30;17(6):652-659. doi: 10.6026/97320630017652. eCollection 2021. Bioinformation. 2021. PMID: 35173388 Free PMC article.
References
-
- Selmer R. Blood pressure and twenty-year mortality in the City of Bergen, Norway. Am J Epidemiol. 1992;136:428–440. - PubMed
-
- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913. - PubMed
-
- Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation. 2005;112:1651–1662. - PubMed
-
- Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–762. - PubMed
-
- Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199–206. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous